The role of mitogen-activated protein kinase pathways in Alzheimer's disease

NeuroSignals

Volumn 11, Issue 5, 2002, Pages 270-281

  Zhu, Xiongwei ^a   Lee, Hyoung Gon ^a   Raina, Arun K ^a   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Amyloid precursor protein; c Jun N terminal kinase; Extracellular signal regulated kinase; p38; Signal transduction

Indexed keywords

JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; STRESS ACTIVATED PROTEIN KINASE; AMYLOID PRECURSOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ALZHEIMER DISEASE; BRAIN INJURY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HUMAN; LONG TERM POTENTIATION; MICROTUBULE; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PURKINJE CELL; REVIEW; SEIZURE; SUBSTANTIA NIGRA; TRANSCRIPTION INITIATION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; NERVOUS SYSTEM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NERVOUS SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 0036770144     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067426     Document Type: Review

References (146)

1. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
2. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
3. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
4. Grewal SS, York RD, Stork PJ: Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 1999;9:544-553.
5. Derkinderen P, Enslen H, Girault JA: The ERK/MAP-kinases cascade in the nervous system. Neuroreport 1999;10:R24-34.
6. Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C: Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology 1997;138:4301-4307.
7. Kim JH, Liao D, Lau LF, Huganir RL: SynGAP: A synaptic RasGAP that associates with the PSD-95/SAP90 protein family. Neuron 1998;20:683-691.
8. Rosen LB, Ginty DD, Weber MJ, Greenberg ME: Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 1994;12:1207-1221.
9. Fiore RS, Murphy TH, Sanghera JS, Pelech SL, Baraban JM: Activation of p42 mitogen-activated protein kinase by glutamate receptor stimulation in rat primary cortical cultures. J Neurochem 1993;61:1626-1633.
10. Vincent SR, Sebben M, Dumuis A, Bockaert J: Neurotransmitter regulation of MAP kinase signaling in striatal neurons in primary culture. Synapse 1998;29:29-36.
11. Frodin M, Gammeltoft S: Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
12. Sweatt JD: The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1-10.
13. Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA: Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature 1995;376:524-527.
14. Finkbeiner S, Greenberg ME: Ca(2+)-dependent routes to Ras: Mechanisms for neuronal survival, differentiation, and plasticity? Neuron 1996;16:233-236.
15. English JD, Sweatt JD: A requirement for the mitogen-activated protein kinase cascade in hippocampal long-term potentiation. J Biol Chem 1997;272:19103-19106.
16. Rosenblum K, Futter M, Voss K, et al: The role of extracellular regulated kinases I/II in latephase long-term potentiation. J Neurosci 2002;22:5432-5441.
17. Coogan AN, O'Leary DM, O'Connor JJ: P42/44 MAP kinase inhibitor PD98059 attenuates multiple forms of synaptic plasticity in rat dentate gyrus in vitro. J Neurophysiol 1999;81:103-110.
18. Kawasaki H, Fujii H, Gotoh Y, et al: Requirement for mitogen-activated protein kinase in cerebellar long-term depression. J Biol Chem 1999;274:13498-13502.
19. 2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron 1998;21:869-883.
20. Thiels E, Kanterewicz BI, Norman ED, Trzaskos JM, Klann E: Long-term depression in the adult hippocampus in vivo involves activation of extracellular signal-regulated kinase and phosphorylation of Elk-1. J Neurosci 2002;22: 2054-2062.
21. Berman DE, Hazvi S, Rosenblum K, Seger R, Dudai Y: Specific and differential activation of mitogen-activated protein kinase cascades by unfamiliar taste in the insular cortex of the behaving rat. J Neurosci 1998;18:10037-10044.
22. Blum S, Moore AN, Adams F, Dash PK: A mitogen-activated protein kinase cascade in the CA1/CA2 subfield of the dorsal hippocampus is essential for long-term spatial memory. J Neurosci 1999;19:3535-3544.
23. Gass P, Kiessling M, Bading H: Regionally selective stimulation of mitogen activated protein (MAP) kinase tyrosine phosphorylation after generalized seizures in the rat brain. Neurosci Lett 1993;162:39-42.
24. Baraban JM, Fiore RS, Sanghera JS, Paddon HB, Pelech SL: Identification of p42 mitogen-activated protein kinase as a tyrosine kinase substrate activated by maximal electroconvulsive shock in hippocampus. J Neurochem 1993;60:330-336.
25. Sugino T, Nozaki K, Takagi Y, et al: Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J Neurosci 2000;20:4506-4514.
26. Gu Z, Jiang Q, Zhang G: Extracellular signal-regulated kinase 1/2 activation in hippocampus after cerebral ischemia may not interfere with postischemic cell death. Brain Res 2001;901:79-84.
27. Mori T, Wang X, Jung JC, et al: Mitogen-activated protein kinase inhibition in traumatic brain injury: In vitro and in vivo effects. J Cereb Blood Flow Metab 2002;22:444-452.
28. Otani N, Nawashiro H, Fukui S, et al: Differential activation of mitogen-activated protein kinase pathways after traumatic brain injury in the rat hippocampus. J Cereb Blood Flow Metab 2002;22:327-334.
29. Kulich SM, Chu CT: Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: Implications for Parkinson's disease. J Neurochem 2001;77:1058-1066.
30. Mielke K, Herdegen T: JNK and p38 stresskinases - Degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000;61:45-60.
31. Yang D, Tournier C, Wysk M, et al: Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 1997;94:3004-3009.
32. Derijard B, Raingeaud J, Barrett T, et al: Independent human MAP-kinase signal transduc-tion pathways defined by MEK and MKK iso-forms. Science 1995;267:682-685.
33. Coso OA, Chiariello M, Yu JC, et al: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995;81:1137-1146.
34. Gupta S, Barrett T, Whitmarsh AJ, et al: Selective interaction of JNK protein kinase iso-forms with transcription factors. EMBO J 1996;15:2760-2770.
35. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH: Stress-activated protein kinase/ c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 1997;68:1736-1744.
36. Yang DD, Kuan CY, Whitmarsh AJ, et al: Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997;389:865-870.
37. Xu X, Raber J, Yang D, Su B, Mucke L: Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. Proc Natl Acad Sci USA 1997;94:12655-12660.
38. Brecht S, Simler S, Vergnes M, Mielke K, Marescaux C, Herdegen T: Repetitive electrocon-vulsive seizures induce activity of c-Jun N-terminal kinase and compartment-specific desensitization of c-Jun phosphorylation in the rat brain. Brain Res Mol Brain Res 1999;68:101-108.
39. Migheli A, Piva R, Atzori C, Troost D, Schiffer D: c-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyo-trophic lateral sclerosis. J Neuropathol Exp Neurol 1997;56:1314-1322.
40. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
41. Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ: Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: Role of caspases, ROS, and JNK. J Neurosci Res 1999;57:86-94.
42. Harper SJ, LoGrasso P: Signalling for survival and death in neurones: The role of stress-activated kinases, JNK and p38. Cell Signal 2001; 13:299-310.
43. Oo TF, Henchcliffe C, James D, Burke RE: Expression of c-fos, c-jun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the sub-stantia nigra. J Neurochem 1999;72:557-564.
44. Mielke K, Brecht S, Dorst A, Herdegen T: Activity and expression of JNK1, p38 and ERK kinases, c-Jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures. Neuroscience 1999;91:471-483.
45. DiCamillo AM, Neff NT, Carswell S, Haun FA: Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP-1347/KT-7515 in rats with lesions of nucleus basalis magnocellularis. Neuroscience 1998;86:473-483.
46. Stein B, Yang MX, Young DB, et al: p38-2, a novel mitogen-activated protein kinase with distinct properties. J Biol Chem 1997;272: 19509-19517.
47. Jiang Y, Chen C, Li Z, et al: Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996;271:17920-17926.
48. Li Z, Jiang Y, Ulevitch RJ, Han J: The primary structure of p38 gamma: A new member of p38 group of MAP kinases. Biochem Biophys Res Commun 1996;228:334-340.
49. Jiang Y, Gram H, Zhao M, et al: Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem 1997;272: 30122-30128.
50. Takekawa M, Posas F, Saito H: A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress-induced activation of the p38 and JNK pathways. EMBO J 1997;16:4973-4982.
51. Coogan AN, O'Neill LA, O'Connor JJ: The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience 1999;93:57-69.
52. Sugino T, Nozaki K, Takagi Y, et al: Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J Neurosci 2000;20:4506-4514.
53. Walton KM, DiRocco R, Bartlett BA, et al: Activation of p38MAPK in microglia after ischemia. J Neurochem 1998;70:1764-1767.
54. Irving EA, Barone FC, Reith AD, Hadingham SJ, Parsons AA: Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 2000;77:65-75.
55. Barone FC, Parsons AA: Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investig Drugs 2000;9:2281-2306.
56. Smith MA: Alzheimer disease. Int Rev Neurobiol 1998;42:1-54.
57. Trojanowski JQ, Mawal-Dewan M, Schmidt ML, Martin J, Lee VM: Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Res 1993;618:333-337.
58. Hyman BT, Elvhage TE, Reiter J: Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am J Pathol 1994;144:565-572.
59. Perry G, Roder H, Nunomura A, et al: Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999;10:2411-2415.
60. Zhu X, Castellani RJ, Takeda A, et al: Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: The 'two hit' hypothesis. Mech Ageing Dev 2001;123:39-46.
61. Ferrer I, Blanco R, Carmona M, et al: Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001;11:144-158.
62. McShea A, Zelasko DA, Gerst JL, Smith MA: Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli. Brain Res 1999;815:237-242.
63. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA: Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 2000;61:128-133.
64. Zhu X, Raina AK, Smith MA: Cell cycle events in neurons. Proliferation or death? Am J Pathol 1999;155:327-329.
65. Anderson AJ, Su JH, Cotman CW: DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996;16:1710-1719.
66. Smith MA, Zhu X, Sun Z, Perry G: Activation of c-Jun in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:546.
67. Atzori C, Ghetti B, Piva R, et al: Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001;60:1190-1197.
68. Shoji M, Iwakami N, Takeuchi S, et al: JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res 2000;85:221-233.
69. Zhu X, Raina AK, Rottkamp CA, et al: Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001;76:435-441.
70. Zhu X, Raina AK, Boux H, Simmons ZL, Takeda A, Smith MA: Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int J Dev Neurosci 2000;18:433-437.
71. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G: Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000;2:413-420.
72. Zhu X, Rottkamp CA, Zevez K, Atwood CS, Perry G, Smith MA: Metal-mediated amyloid-beta toxicity acts through the activation of JNK/SAPK pathway in Alzheimer disease. Free Radic Biol Med 2001;31:S65.
73. Smith MA, Harris PL, Sayre LM, Perry G: Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868.
74. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA: Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000;59:880-888.
75. Hensley K, Floyd RA, Zheng NY, et al: p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999;72:2053-2058.
76. Ferrer I, Blanco R, Carmona M, Puig B: Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/ JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 2001; 108:1397-1415.
77. Zhu X, Rottkamp CA, Hartzler A, et al: Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001;79: 311-318.
78. Gomez-Isla T, Hollister R, West H, et al: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
79. Wisniewski HM, Narang HK, Terry RD: Neurofibrillary tangles of paired helical filaments. J Neurol Sci 1976;27:173-181.
80. Morishima-Kawashima M, Hasegawa M, Takio K, et al: Hyperphosphorylation of tau in PHF. Neurobiol Aging 1995;16:365-380.
81. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998;71:2465-2476.
82. Hall GF, Lee VM, Lee G, Yao J: Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol 2001;158:235-246.
83. Alonso AC, Grundke-Iqbal I, Iqbal K: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996; 2:783-787.
84. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH: Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 1997;69:191-198.
85. Roder HM, Eden PA, Ingram VM: Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Commun 1993;193: 639-647.
86. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 1997;409:57-62.
87. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH: Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 1997;68:1736-1744.
88. Blanchard BJ, devi Raghunandan R, Roder HM, Ingram VM: Hyperphosphorylation of human TAU by brain kinase PK40erk beyond phosphorylation by cAMP-dependent PKA: Relation to Alzheimer's disease. Biochem Biophys Res Commun 1994;200:187-194.
89. Drewes G, Lichtenberg-Kraag B, Doring F, et al: Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 1992;11:2131-2138.
90. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH: Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 2000;74:1587-1595.
91. Lu Q, Wood JG: Functional studies of Alzheimer's disease tau protein. J Neurosci 1993; 13:508-515.
92. Ekinci FJ, Shea TB: Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: Additive and synergistic influence of alteration of additional kinase activities. Cell Mol Neurobiol 1999;19:249-260.
93. Guise S, Braguer D, Carles G, Delacourte A, Briand C: Hyperphosphorylation of tau is mediated by ERK activation during antican-cer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res 2001;63:257-267.
94. Garver TD, Oyler GA, Harris KA, et al: Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. Mol Pharmacol 1995; 47:745-756.
95. Rapoport M, Ferreira A: PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 2000;74:125-133.
96. Greenberg SM, Koo EH, Selkoe DJ, Qiu WQ, Kosik KS: Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci USA 1994;91:7104-7108.
97. Lovestone S, Reynolds CH, Latimer D, et al: Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994;4:1077-1086.
98. Latimer DA, Gallo JM, Lovestone S, et al: Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyper-phosphorylation of transfected tau. FEBS Lett 1995;365:42-46.
99. Holzer M, Rodel L, Seeger G, et al: Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology. Neuroscience 2001;105:1041-1054.
100. Tomidokoro Y, Ishiguro K, Harigaya Y, et al: Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett 2001;299:169-172.
101. Knowles RB, Chin J, Ruff CT, Hyman BT: Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: Implications for MAP kinase activation in Alzheimer disease. J Neuropathol Exp Neurol 1999;58:1090-1098.
102. Jenkins SM, Zinnerman M, Garner C, Johnson GV: Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 2000;345/2:263-270.
103. Buee-Scherrer V, Goedert M: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett 2002;515:151-154.
104. Planel E, Yasutake K, Fujita SC, Ishiguro K: Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001;276:34298-34306.
105. Shanavas A, Papasozomenos SC: Tau kinases in the rat heat shock model: Possible implications for Alzheimer disease. Proc Natl Acad Sci USA 2000;97:14139-14144.
106. Selkoe DJ: Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996;271:18295-18298.
107. Wei W, Wang X, Kusiak JW: Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 2002;277:17649-17656.
108. Troy CM, Rabacchi SA, Xu Z, et al: Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001;77:157-164.
109. Morishima Y, Gotoh Y, Zieg J, et al: Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001;21:7551-7560.
110. Bozyczko-Coyne D, O'Kane TM, Wu ZL, et al: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 2001;77:849-863.
111. Santiard-Baron D, Gosset P, Nicole A, Sinet PM, Christen Y, Ceballos-Picot I: Identification of beta-amyloid-responsive genes by RNA differential display: Early induction of a DNA damage-inducible gene, gadd45. Exp Neurol 1999;158:206-213.
112. Estus S, Tucker HM, van Rooyen C, et al: Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant 'apoptotic' pattern of gene induction. J Neurosci 1997;17:7736-7745.
113. Anderson AJ, Pike CJ, Cotman CW: Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): Association of c-Jun with A beta-induced apoptosis. J Neurochem 1995;65: 1487-1498.
114. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW: Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002;22:3376-3385.
115. Rottkamp CA, Raina AK, Zhu X, et al: Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001;30:447-450.
116. Kuperstein F, Yavin E: ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. Eur J Neurosci 2002;16:44-54.
117. Ekinci FJ, Malik KU, Shea TB: Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J Biol Chem 1999;274:30322-30327.
118. Abe K, Saito H: Amyloid beta neurotoxicity not mediated by the mitogen-activated protein kinase cascade in cultured rat hippocampal and cortical neurons. Neurosci Lett 2000; 292:1-4.
119. Tong L, Thornton PL, Balazs R, Cotman CW: Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem 2001;276:17301-17306.
120. Sato N, Kamino K, Tateishi K, et al: Elevated amyloid beta protein(1-40) level induces CREB phosphorylation at serine-133 via p44/42 MAP kinase (Erk1/2)-dependent pathway in rat pheochromocytoma PC12 cells. Biochem Biophys Res Commun 1997;232:637-642.
121. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD: Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
122. Stein TD, Johnson JA: Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002;22:7380-7388.
123. Daniels WM, Hendricks J, Salie R, Taljaard JJ: The role of the MAP-kinase superfamily in beta-amyloid toxicity. Metab Brain Dis 2001; 16:175-185.
124. Selkoe DJ: Alzheimer's disease: Genotypes, phenotypes, and treatments. Science 1997; 275:630-631.
125. Desdouits-Magnen J, Desdouits F, Takeda S, et al: Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 1998;70:524-530.
126. Mills J, Laurent Charest D, Lam F, et al: Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 1997;17:9415-9422.
127. Avramovich Y, Amit T, Youdim MB: Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 2002;277:31466-31473.
128. Manthey D, Heck S, Engert S, Behl C: Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem 2001; 268:4285-4291.
129. Goodenough S, Engert S, Behl C: Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci Lett 2000;296:49-52.
130. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V: Regulated secretion of amyloid precursor protein by TrkA receptor stimulation in rat pheochromocytoma-12 cells is mitogen activated protein kinase sensitive. Neurosci Lett 1999;271:97-100.
131. Palacino JJ, Berechid BE, Alexander P, et al: Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells. J Biol Chem 2000;275:215-222.
132. Villa A, Latasa MJ, Pascual A: Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J Neuro-chem 2001;77:1077-1084.
133. Murayama Y, Takeda S, Yonezawa K, Giambarella U, Nishimoto I, Ogata E: Cell surface receptor function of amyloid precursor protein that activates Ser/Thr kinases. Gerontology 1996;42(suppl 1):2-11.
134. Grant SM, Morinville A, Maysinger D, Szyf M, Cuello AC: Phosphorylation of mitogen-activated protein kinase is altered in neuroectodermal cells overexpressing the human amyloid precursor protein 751 isoform. Brain Res Mol Brain Res 1999;72:115-120.
135. Wallace WC, Akar CA, Lyons WE, Kole HK, Egan JM, Wolozin B: Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Brain Res Mol Brain Res 1997;52:213-227.
136. Meng JY, Kataoka H, Itoh H, Koono M: Amyloid beta protein precursor is involved in the growth of human colon carcinoma cell in vitro and in vivo. Int J Cancer 2001;92:31-39.
137. Mitsuda N, Ohkubo N, Tamatani M, et al: Activated cAMP-response element-binding protein regulates neuronal expression of pre-senilin-1. J Biol Chem 2001;276:9688-9698.
138. Mudher A, Chapman S, Richardson J, et al: Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J Neurosci 2001;21:4987-4995.
139. Standen CL, Brownlees J, Grierson AJ, et al: Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem 2001;76:316-320.
140. Matsuda S, Yasukawa T, Homma Y, et al: c-Jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1 scaffolds Alzheimer's amyloid precursor protein with JNK. J Neurosci 2001;21:6597-6607.
141. Taru H, Iijima K, Hase M, Kirino Y, Yagi Y, Suzuki T: Interaction of Alzheimer's beta-amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade. J Biol Chem 2002;277:20070-20078.
142. Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D'Adamio L: Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP). J Biol Chem 2002;277:3767-3775.
143. Taru H, Kirino Y, Suzuki T: Differential roles of JIP scaffold proteins in the modulation of amyloid precursor protein metabolism. J Biol Chem 2002;277:27567-27574.
144. Hashimoto Y, Niikura T, Ito Y, Nishimoto I: Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein. J Biol Chem 2000;275:34541-34551.
145. Matsuda S, Yasukawa T, Homma Y, et al: c-Jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1 scaffolds Alzheimer's amyloid precursor protein with JNK. J Neurosci 2001;21:6597-6607.
146. Kim JW, Chang TS, Lee JE, et al: Negative regulation of the SAPK/JNK signaling pathway by presenilin 1. J Cell Biol 2001;153: 457-463.